medical-marketing.us@horiba.com
  • Facebook
  • Twitter
  • RSS
  • Facebook
  • Twitter
  • RSS
MENUMENU
  • Our Story
        • Our Vision
        • Our History
        • Our Brands
  • Care Pathways
        • Hospitals
        • Opioid Crisis Task Force
        • Physician Office Labs
        • Pain Management
        • Decentralized Testing
  • Solutions
        • Drugs of Abuse Testing
          • Drug Screening
          • Drug Confirmation
        • General Chemistry
        • Hematology Testing
  • Products
        • Clinical Chemistry Analyzers
          • Mindray BS-200
          • Mindray BS-480
          • Mindray BA-800M
          • Pointe Impulse ISE
          • Pointe 180
          • Pointe 180 Quick Touch
          • Pointe 180 II
        • Hematology Analyzers
          • Mindray BC-3600 (3pt)
          • Mindray BC-5390 (5pt)
        • Reagents
          • General Chemistry
            • Open Channel
            • Instrument Specific
            • Calibrators, Controls and Standards
          • Drugs of Abuse
            • Open Channel
            • Calibrators and Controls
          • Enzyme Immunoassay Kits
        • LC/MS Confirmation
          • LC/MS Total Solution
          • Method Consultation & Implementation
          • Ready-to-Use Calibrators and Controls
        • Service
          • Cost Per Screen Program
        • View HORIBA Medical Products Here
  • Knowledge Center
        • Product Information
          • Brochures
          • Sell Sheets
          • Infographics
        • Educational Resources
          • Webinars
          • Customer Testimonials
        • Product Documentation
          • Product Inserts
          • SDS
          • Manuals
          • Regulatory Documents
        • Latest Webinar – Watch Now

  • Newsroom
        • Latest News
        • Events
  • Contact Us
  • Login
  • Terms and Conditions
  • EMAIL HERE FOR PRODUCT INFORMATION

Centrality of G6PD in COVID-19: The Biochemical Rationale and Clinical Implications

Nov 24, 2020 | Health and Well Being

Centrality of G6PD in COVID-19: The Biochemical Rationale and Clinical Implications Front Med (Lausanne). 2020 Oct 22;7:584112. doi: 10.3389/fmed.2020.584112. eCollection 2020.   November 2020  ABSTRACT Introduction: COVID-19 is a novel and devastating disease....

Methemoglobinemia in Patient with G6PD Deficiency and SARS-CoV-2 Infection

Aug 7, 2020 | Health and Well Being

Methemoglobinemia in Patient with G6PD Deficiency and SARS-CoV-2 Infection — Volume 26, Number 9—September 2020; Research Letter by Kieran Palmer, Jonathan Dick, Winifred French, Lajos Floro, and Martin Ford Author affiliations: King’s College Hospital National Health...

Glucose-6-Phosphate Dehydrogenase Deficiency: An Actionable Risk Factor for Patients with COVID-19?

Jun 18, 2020 | Health and Well Being

Glucose-6-Phosphate Dehydrogenase Deficiency: An Actionable Risk Factor for Patients with COVID-19?   June 7, 2020 – Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common X-linked mutation that is more prevalent in African, Asian, Latin American and...

Does G6PD Deficiency Relate to COVID-19 Infection?

Apr 14, 2020 | Health and Well Being

Does G6PD Deficiency Relate to COVID-19 Infection? — Several hints of one, pointing to need for focused research  by Dan J. Vick MD, DHA, MBA, CPE   April 2020 - In an April 8 MedPage Today article, Mark Zucker, MD, asked the question as to why there is...

Categories

  • Health and Well Being
  • Press Releases
  • Product and Innovation
  • SDS
  • Webinars
  • Facebook
  • Twitter
  • RSS
Copyright © 1998-2019 MedTest Dx. All information deemed reliable, but not guaranteed.
 

Loading Comments...